Nascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors

Rhea-AI Summary

Nascent Biotech (OTCQB:NBIO) announced that its CEO, Sean Carrick, was interviewed by Proactive Investors, discussing the company's progress with its Phase I Clinical Trial for Pritumumab (PTB), a monoclonal antibody targeting cancers originating in epithelial cells. Carrick emphasized the company's ongoing development of PTB, with plans to advance to Phase II trials, which could significantly benefit shareholders. The interview highlighted milestones achieved in monoclonal antibody development and a vaccine platform utilizing r-BCG to combat viral infections.

Positive

• Progress in Phase I Clinical Trial for Pritumumab (PTB) indicates potential for advancement to Phase II.
• Development of PTB is aimed at treating deadly brain cancers, showcasing a strategic focus on high-impact areas.
• Milestones achieved in monoclonal antibody development and vaccine platform using r-BCG could enhance company value.

Negative

• None.

VERO BEACH, FL / ACCESSWIRE / May 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers, is pleased to announce that its CEO, Sean Carrick, was recently interviewed by Proactive Investors (ProactiveInvestors.com), providing a brief history of Nascent Biotech as well as fresh insights into the current state of the Company and its progress toward achieving its vision.

The complete interview may be viewed HERE.

Mr. Carrick stated, "The Company is moving forward as expected with our Phase I Clinical Trial. In the process, we are learning a lot about PTB. We believe that, as we progress forward with the phase I Clinical Trial and move into phase II, achievement of our milestones will drive significant value for the Company and our shareholders."

Pritumumab (PTB) is a unique monoclonal antibody that attacks cancers originating in epithelial cells - the cells that line the organs of the body.

During the interview Mr. Carrick updated current and prospective shareholders on recent milestones achieved by the Company including:

• Nascent is at the leading edge of natural, patient-derived monoclonal antibody development with the Company's PTB monoclonal antibody solution benefitting from a well-defined regulatory and clinical development strategy toward the treatment of deadly brain cancers.
• The vaccine development platform, using A recombinant Bacillus Calmette-Guerin (r-BCG), continues to progress and is intended to be used against viruses around the world.

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB:NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping millions of people worldwide. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com. Our lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that will be studied in Phase I clinical trials for the treatment of Brain Cancer. Development for PTB as a treatment for COVID-19 is being researched.

For further information please visit our website www.nascentbiotech.com.

Forward Looking Safe Harbor Statement

Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact
Sean Carrick
President | CEO
Nascent Biotech, Inc.
772.713.0541 Cell
sean.carrick@nascentbiotech.com

Public Relations
EDM Media, LLC
https://edm.media

SOURCE: Nascent Biotech Inc.

View source version on accesswire.com:
https://www.accesswire.com/699981/Nascent-Biotechs-CEO-Sean-Carrick-Featured-in-In-Depth-Interview-with-Proactive-Investors

FAQ

What updates did Nascent Biotech provide regarding its Phase I Clinical Trial for NBIO?

Nascent Biotech updated that it is progressing well in its Phase I Clinical Trial for Pritumumab (PTB) and aims to move into Phase II.

What is Pritumumab (PTB) and its significance for Nascent Biotech?

Pritumumab (PTB) is a monoclonal antibody developed by Nascent Biotech to target brain cancers, representing a critical component of its therapeutic pipeline.

How does Nascent Biotech's vaccine platform work?

Nascent Biotech's vaccine platform uses recombinant Bacillus Calmette-Guerin (r-BCG) and is intended for global viral infection prevention.

Who conducted the recent interview with Nascent Biotech's CEO?

Sean Carrick, CEO of Nascent Biotech, was interviewed by Proactive Investors discussing the company's advancements and future goals.

What future steps does Nascent Biotech plan to take in its clinical trials?

Nascent Biotech plans to progress its Phase I Clinical Trial of Pritumumab (PTB) into Phase II, aiming to achieve significant milestones.